Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02416388
Title Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital, Angers
Indications

acute myeloid leukemia

Therapies

Cytarabine + Daunorubicin

Cytarabine + Vosaroxin

Cytarabine

Methotrexate + Mycophenolic Acid

Cyclosporine + Mycophenolic Acid

Cytarabine + Venetoclax

Cytarabine + Dexamethasone

Cyclosporine

Cytarabine + Idarubicin

Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.